Evidence map›Paper›PMID 42366734›Full record

ArticleBiotechnology and bioengineering2026

Minimizing Off-Target Effects of CRISPR-Cas9 With Optimized sgRNA: Evaluation of Efficiency and Specificity in the Tumor Protein 53 (TP53) Region.

Ali Mertcan Köse, Monia Ranalli, Drenka Trivanovic, Irina Maslovaric

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ali Mertcan KöseDepartment of Statistics, Suleyman Demirel University, Isparta, Turkey.ORCID https://orcid.org/0000-0002-5464-9441
Monia RanalliDepartment of Statistics, Sapienza University, Rome, Italy.ORCID https://orcid.org/0000-0001-7193-8803
Drenka TrivanovicInstitute for Medical Research, University of Belgrade, National Institute of the Republic of Serbia, Belgrade, Serbia.ORCID https://orcid.org/0000-0001-7041-3917
Irina MaslovaricInstitute for Medical Research, University of Belgrade, National Institute of the Republic of Serbia, Belgrade, Serbia.ORCID https://orcid.org/0000-0003-0892-5617

Funding

Ministry of Science, Technological Development, and Innovation of the Republic of Serbia
6 · The paper itself

Abstract

CRISPR-Cas9 is a widely used genetic tool with therapeutic potential in molecular biology. CRISPR-Cas9 enables precise genome editing by its ability to target specific DNA sequence. After off-target and on-target regions are identified, CRISPR-Cas9 is applied to these regions based on the match between the guide RNA (gRNA) and target DNA sequence. This study points to the off-target impact of mismatches between the gRNA and target DNA on exon regions of the TP53 gene, which are involved in regulating multiple genes and cellular functions. Off-target positions are typically evaluated using scoring methods. In this study, we have used latent class analysis to reveal subclasses of off-target positions. Thus, we have created the levels of off-target positions and evaluated the effects of mismatching positions within these classes using machine learning classifiers. The results revealed that mismatching positions could be categorized into three levels: low, middle, and high off-target positions. We have improved a computational framework to minimize off-target effects and to identify the PAM sequences in the gRNA design. Thus, carefully designed gRNAs will ensure that desired genetic edits are performed and target variants are achieved. This work will avail the future research aimed at optimizing genome editing by customizing CRISPR-Cas9 to target specific protospacer DNA through gRNA.

Indexed as

CRISPR-Cas SystemsGene EditingRNA, Guide, CRISPR-Cas SystemsTumor Suppressor Protein p53HumansMachine LearningRNA, Guide, CRISPR-Cas SystemsTP53 protein, humanTumor Suppressor Protein p53CRISPRlatent class analysislevels of off‐targetmachine learningtumor protein 53

Identifiers

PMID42366734
PMCPMC13576857

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.